
OMEMI #AHA20

Trial Description: Elderly patients with recent MI were randomized to 1.8 g n-3 fatty acids (n = 513) vs. placebo (n = 514). The study medication contained 930 g of EPA and 660 g of DHA.



RESULTS

- Primary outcome: all-cause death, nonfatal MI, unscheduled revascularization (stent or bypass surgery), stroke, or hospitalization for HF at 24 months occurred in 21.0% of the PUFA group vs. 19.8% of placebo group (p = 0.62)
- Secondary outcomes: ٠
 - Atrial fibrillation: 7.2% of the PUFA group vs. 4.0% of the placebo group (p = 0.06)
 - Major bleeding: 10.7% of the PUFA group vs. 11.0% of the placebo group (p = 0.87)

CONCLUSIONS

- This trial failed to show that PUFA was superior to placebo at preventing adverse cardiovascular outcomes
- Among elderly patients with recent MI, PUFA was not beneficial

Kalstad AA, et al. Circulation 2020;Nov 15:[Epub]



AMERICAN COLLEGE of CARDIOLOGY